Smoking and Parkinson disease
暂无分享,去创建一个
M. Loriot | B. Ritz | J. Bronstein | A. Elbaz | C. Mulot | K. Paul | Ismaïl Ahmed | P. Lee
[1] M. Morissette,et al. Metabotropic glutamate receptors as therapeutic targets in Parkinson's disease: An update from the last 5 years of research , 2017, Neuropharmacology.
[2] G. Kullak-Ublick,et al. Vitamin D3 transactivates the zinc and manganese transporter SLC30A10 via the Vitamin D receptor , 2016, The Journal of Steroid Biochemistry and Molecular Biology.
[3] D. Jennings,et al. A Phase 1 Clinical Study of the Retinoid X Receptor (RXR) Selective Agonist IRX4204 in Patients with Early Parkinson’s Disease (PD) (P2.342) , 2016 .
[4] B. Blumberg,et al. Selective brain penetrable Nurr1 transactivator for treating Parkinson's disease , 2016, Oncotarget.
[5] Liang Shen,et al. Associations between Vitamin D Status, Supplementation, Outdoor Work and Risk of Parkinson’s Disease: A Meta-Analysis Assessment , 2015, Nutrients.
[6] M. Goldberg,et al. Association of Parkinson’s Disease and Its Subtypes with Agricultural Pesticide Exposures in Men: A Case–Control Study in France , 2015, Environmental health perspectives.
[7] Chuong B. Do,et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease , 2014, Nature Genetics.
[8] K. Mcfarland,et al. Low dose bexarotene treatment rescues dopamine neurons and restores behavioral function in models of Parkinson's disease. , 2013, ACS chemical neuroscience.
[9] Y. Nolan,et al. Parkinson's disease in the nuclear age of neuroinflammation. , 2013, Trends in molecular medicine.
[10] A. Lees,et al. Meta-Analysis of Early Nonmotor Features and Risk Factors for Parkinson Disease , 2012, Annals of neurology.
[11] O. Dı́az-Ruiz,et al. Early post-treatment with 9-cis retinoic acid reduces neurodegeneration of dopaminergic neurons in a rat model of Parkinson’s disease , 2012, BMC Neuroscience.
[12] Juan Pablo Lewinger,et al. Invited commentary: GE-Whiz! Ratcheting gene-environment studies up to the whole genome and the whole exposome. , 2012, American journal of epidemiology.
[13] C. Magnani,et al. Kin‐cohort analysis of LRRK2‐G2019S penetrance in Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.
[14] L. Descarries,et al. Enhanced Sucrose and Cocaine Self-Administration and Cue-Induced Drug Seeking after Loss of VGLUT2 in Midbrain Dopamine Neurons in Mice , 2011, The Journal of Neuroscience.
[15] J. Houeto,et al. Impact of recommendations on the initial therapy of Parkinson's disease: a population-based study in France. , 2011, Parkinsonism & related disorders.
[16] A. Işık,et al. Effects of pioglitazone and retinoic acid in a rotenone model of Parkinson's disease , 2011, Brain Research Bulletin.
[17] H. Adami,et al. Epidemiology and etiology of Parkinson’s disease: a review of the evidence , 2011, European Journal of Epidemiology.
[18] Eric J Tchetgen Tchetgen,et al. On the robustness of tests of genetic associations incorporating gene-environment interaction when the environmental exposure is misspecified. , 2011, Epidemiology.
[19] M. Loriot,et al. Interaction between ABCB1 and professional exposure to organochlorine insecticides in Parkinson disease. , 2010, Archives of neurology.
[20] B. Ritz,et al. After half a century of research on smoking and PD, where do we go now? , 2010, Neurology.
[21] D. Thomas,et al. Gene–environment-wide association studies: emerging approaches , 2010, Nature Reviews Genetics.
[22] Dong Sun Kim,et al. Epigenetic inactivation of retinoid X receptor genes in non-small cell lung cancer and the relationship with clinicopathologic features. , 2010, Cancer genetics and cytogenetics.
[23] S. Friling,et al. Activation of Retinoid X Receptor increases dopamine cell survival in models for Parkinson's disease , 2009, BMC Neuroscience.
[24] Jaeil Ahn,et al. Tests for gene‐environment interaction from case‐control data: a novel study of type I error, power and designs , 2008, Genetic epidemiology.
[25] Eden R Martin,et al. A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms , 2008, Genetic epidemiology.
[26] P. Wilce,et al. Smoking and alcoholism target genes associated with plasticity and glutamate transmission in the human ventral tegmental area. , 2007, Human molecular genetics.
[27] Manuel A. R. Ferreira,et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.
[28] E. Hirsch,et al. Altered expression of vesicular glutamate transporters VGLUT1 and VGLUT2 in Parkinson disease , 2007, Neurobiology of Aging.
[29] Gunnel Tybring,et al. Quality and Quantity of Saliva DNA Obtained from the Self-administrated Oragene Method—A Pilot Study on the Cohort of Swedish Men , 2006, Cancer Epidemiology Biomarkers & Prevention.
[30] C. Tzourio,et al. Cigarette smoking and Parkinson's disease: A case–control study in a population characterized by a high prevalence of pesticide exposure , 2005, Movement disorders : official journal of the Movement Disorder Society.
[31] J. Rothstein,et al. Glutamate transporters: animal models to neurologic disease , 2004, Neurobiology of Disease.
[32] T. Willson,et al. Pxr, car and drug metabolism , 2002, Nature Reviews Drug Discovery.
[33] F. Alla,et al. Retinoic acid receptor and retinoid X receptor alterations in lung cancer precursor lesions. , 2000, Cancer research.
[34] D. Maraganore,et al. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990 , 1999, Neurology.
[35] J W Langston,et al. Parkinson disease in twins: an etiologic study. , 1999, JAMA.
[36] P Chambon,et al. Impaired locomotion and dopamine signaling in retinoid receptor mutant mice. , 1998, Science.
[37] P. Chambon,et al. Regulation of dopaminergic pathways by retinoids: activation of the D2 receptor promoter by members of the retinoic acid receptor-retinoid X receptor family. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[38] W D Flanders,et al. Sample size requirements in case-only designs to detect gene-environment interaction. , 1997, American journal of epidemiology.
[39] Richard H. P. Porter,et al. Glutamate and Parkinson’s disease , 1996, Molecular Neurobiology.
[40] Xiang‐Dong Wang,et al. Alcohol and Tobacco Smoke in Retinoid Metabolism and Signaling: Implications for Carcinogenesis , 2006 .